Horizon Therapeutics's revenue for the
three
months ended in Jun. 2023 was $945 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $3,644 Mil.
Horizon Therapeutics's Revenue per Share for the
three
months ended in Jun. 2023 was $4.04.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $15.57.
Warning Sign:
Horizon Therapeutics PLC revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Horizon Therapeutics was -3.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 34.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 21.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 32.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Horizon Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 115.50% per year. The lowest was -9.90% per year. And the median was 22.85% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Horizon Therapeutics's Revenue
For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Horizon Therapeutics's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Horizon Therapeutics's Revenue falls into.
Horizon Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,644 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Horizon Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Horizon Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Horizon Therapeutics (Horizon Therapeutics) Business Description
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HZNP has been successfully added to your 